



# Multidisciplinary Therapy of Pancreas Cancer:

**RECENT ADVANCES AND EMERGING PARADIGMS**

May 3-4, 2019

The University of Texas MD Anderson Cancer Center  
Frank E. Anderson Conference Hall  
1515 Holcombe Boulevard  
Houston, TX 77030


THE UNIVERSITY OF TEXAS

**MDAnderson  
Cancer Center**

Making Cancer History®

## GOAL

This activity will present new treatment options to physicians and affiliated health professionals for patients with pancreatic cancer. In addition, multidisciplinary case studies will be presented highlighting optimal approaches to complex scenarios in this disease. The long-term goal of these efforts is to improve the survival rate of pancreatic cancer patients through evidence based approaches.



## EDUCATIONAL OBJECTIVES

After attending the conference, participants should be able to

- Implement genetic testing of patients and family members to screen for those who are at risk for developing pancreatic cancer and other cancers (*knowledge, competence, performance, patient outcomes*);
- Evaluate, counsel and treat patients with pancreatic cancer at all stages of disease (locally advanced, resectable, borderline resectable, metastatic) (*knowledge, competence, performance, patient outcomes*);
- Provide a comprehensive understanding of innovative and emerging cancer therapies, inclusive of the side effects, to the cancer patient (*knowledge, competence, performance, patient outcomes*); and
- Apprise fellow clinicians and healthcare providers of emerging paradigms of the latest clinical trials and supportive care (*knowledge, competence, performance, patient outcomes*).

## TARGET AUDIENCE

This conference should be of interest to Physicians, Advanced Practice Providers, Nurses, Researchers, Fellows and Trainees.

## EDUCATIONAL METHODS

- Lectures
- Case Study
- Question-and-Answer Session

## EVALUATION

A course evaluation survey will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

## ACCREDITATION/ CREDIT DESIGNATION

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide

continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 10.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## ABIM MAINTENANCE OF CERTIFICATION (MOC)



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to

submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

In order to receive MOC points, you will need to pass the post-test with a score of 70% or higher. You will be able to take the test as many times as you need to in order to pass.

Participant completion data will be shared with and transmitted to the ACCME on the participant's behalf.

## ETHICS

The "Supportive Care" session has been designated by The University of Texas MD Anderson Cancer Center for .75 AMA PRA Category 1 Credits™ in medical ethics and/or professional responsibility.

## CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES

Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting attendance will be emailed when an individual completed the online CME Verification and Evaluation Questionnaire process after the conference.

A record of attendance (certificate) will be available online to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

## MD ANDERSON PROGRAM COMMITTEE MEMBERS

**Robert A. Wolff, MD, Co-Chair**  
*Gastrointestinal Medical Oncology*

**Matthew Katz, MD, Co-Chair**  
*Surgical Oncology*

**Anirban Maitra, MBBS**  
*Pathology, Anatomical*

**Gauri Varadhachary, MBBS, MD**  
*Gastrointestinal Medical Oncology*

**Joseph Herman, MD**  
*Radiation Oncology*

**Shubham Pant, MBBS**  
*Investigational Cancer Therapeutics*

**Bettina Marble, MPA**  
*Sheikh Ahmed Center for Pancreatic Cancer Research*

**Felisha Estelle**  
*CME/Conference Management*

**Kelley Gilpin**  
*CME/Conference Management*

## Program Agenda

### FRIDAY, MAY 3, 2019

- 3:00 pm Registration
- 3:30 **Welcome & Introductions**  
Robert A. Wolff, MD
- 3:45 **Keynote**  
Christopher Lee Wolfgang, MD, MS, PhD

### Translational Talks

- 4:30 **Hereditary Pancreatic Cancer & High Risk Clinic**  
Floencia McAllister, MD
- 5:00 **MD Anderson Cyst Clinic**  
Michael Kim, MD
- 5:30 **Liquid Biopsies in Pancreatic Cancer**  
Anirban Maitra, MBBS
- 6:00 **Imaging Based Biomarkers**  
Eugene Koay, MD, PhD
- 6:30 **Closing Remarks and Adjourn**  
Robert A. Wolff, MD
- 6:35 - 8:30 Welcome Reception

### SATURDAY, MAY 4, 2019

- 8:00 am Registration and Continental Breakfast
- 8:30 **Welcome & Introductions**
- 8:45 **Keynote**  
James Abbruzzese, MD

### Multimodality Treatment

- 9:30 **Preoperative Therapy for Resectable and Borderline Resectable PDAC**  
Matthew Katz, MD
- 10:00 **Adjuvant Therapy for Resected PDAC**  
Michael Pishvaian, MD, PhD
- 10:30 Break

|                                        |                                                                                                                                                                                                                           |
|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10:45                                  | <b>Case Study:</b><br><b>Preoperative Therapy for Resectable and Borderline Resectable PDAC</b><br>Facilitators: Robert A. Wolff, MD, Joseph Herman, MD, David Fogelman, MD, Ching-Wei Tzang, MD and Eugene Koay, MD, PhD |
| 11:05                                  | <b>Case Study:</b><br><b>Adjuvant Therapy for PDAC</b><br>Facilitators: Robert A. Wolff, MD, Joseph Herman, MD, Michael Pishvaian, MD, PhD, Grace Smith, MD and Michael Kim, MD                                           |
| 11:25                                  | <b>Management of Metastatic PDAC</b><br>Michael Overman, MD                                                                                                                                                               |
| 11:55                                  | <b>Role of the Gastroenterologist in PDAC Management</b><br>Manoop Bhutani, MBBS                                                                                                                                          |
| 12:25 pm                               | Lunch (provided)                                                                                                                                                                                                          |
| <b>Emerging Paradigms</b>              |                                                                                                                                                                                                                           |
| 1:30                                   | <b>Landscape of Phase 1 Studies</b><br>Shubham Pant, MBBS                                                                                                                                                                 |
| 2:00                                   | <b>Minimally Invasive Surgical Approaches</b><br>Naruhiko Ikoma, MD                                                                                                                                                       |
| 2:30                                   | <b>Energy Ablative Technologies / IRE</b><br>Ching-Wei Tzeng, MD                                                                                                                                                          |
| 3:00                                   | <b>Emerging Radiation Approaches in PDAC</b><br>Joseph Herman, MD                                                                                                                                                         |
| 3:30                                   | Break                                                                                                                                                                                                                     |
| 3:40                                   | <b>Case Study:</b><br><b>Oligometastatic Disease and Locoregional Intervention</b><br>Facilitators: Milind Javle, MD and Chad Tang, MD                                                                                    |
| 4:10                                   | <b>Case Study:</b><br><b>Sequencing of Therapies for LAPC</b><br>Facilitators: David Fogelman, MD and Sunil Krishnan, MD                                                                                                  |
| <b>Supportive Care (Ethics Credit)</b> |                                                                                                                                                                                                                           |
| 4:40                                   | <b>Nutrition in Pancreatic Cancer</b><br>Maria Petzel, BS                                                                                                                                                                 |
| 5:05                                   | <b>Prioritizing the Patient Experience through Early Integration of Supportive/ Palliative Care</b><br>Ishwaria M. Subbiah, MD                                                                                            |
| 5:30                                   | Adjourn                                                                                                                                                                                                                   |

|                                                                                                                                                                                                                                       |                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| <b>MD ANDERSON FACULTY</b>                                                                                                                                                                                                            |                                                                               |
| <b>Manoop Bhutani, MBBS</b><br><i>Gastroenterology, Hepatology &amp; Nutrition</i>                                                                                                                                                    | <b>Florencia McAllister, MD</b><br><i>Clinical Cancer Prevention</i>          |
| <b>David Fogelman, MD</b><br><i>Gastrointestinal Medical Oncology</i>                                                                                                                                                                 | <b>Michael Overman, MD</b><br><i>Gastrointestinal Medical Oncology</i>        |
| <b>Joseph Herman, MD</b><br><i>Radiation Oncology</i>                                                                                                                                                                                 | <b>Shubham Pant, MBBS</b><br><i>Investigational Cancer Therapeutics</i>       |
| <b>Naruhiko Ikoma, MD</b><br><i>Surgical Oncology</i>                                                                                                                                                                                 | <b>Maria Petzel, BS</b><br><i>Clinical Nutrition</i>                          |
| <b>Milind Javle, MD</b><br><i>Gastrointestinal Medical Oncology</i>                                                                                                                                                                   | <b>Michael Pishvaian, MD, PhD</b><br><i>Gastrointestinal Medical Oncology</i> |
| <b>Matthew Katz, MD</b><br><i>Surgical Oncology</i>                                                                                                                                                                                   | <b>Grace Smith, MD</b><br><i>Radiation Oncology</i>                           |
| <b>Michael Kim, MD</b><br><i>Surgical Oncology</i>                                                                                                                                                                                    | <b>Ishwaria M. Subbiah, MD</b><br><i>Palliative Care</i>                      |
| <b>Eugene Koay, MD, PhD</b><br><i>Radiation Oncology</i>                                                                                                                                                                              | <b>Chad Tang, MD</b><br><i>Radiation Oncology</i>                             |
| <b>Sunil Krishnan, MD</b><br><i>Radiation Oncology</i>                                                                                                                                                                                | <b>Ching-Wei Tzeng, MD</b><br><i>Surgical Oncology</i>                        |
| <b>Anirban Maitra, MBBS</b><br><i>Pathology, Anatomical</i>                                                                                                                                                                           | <b>Robert A. Wolff, MD</b><br><i>Gastrointestinal Medical Oncology</i>        |
| <b>GUEST FACULTY</b>                                                                                                                                                                                                                  |                                                                               |
| <b>James Abbruzzese, MD</b><br><i>Duke University School of Medicine</i><br><i>Chief, Division of Medical Oncology</i><br><i>Member of the Duke Cancer Institute</i><br><i>Professor of Medicine</i><br><i>Durham, North Carolina</i> |                                                                               |
| <b>Christopher Lee Wolfgang, MD, MS, PhD</b><br><i>The Johns Hopkins University School of Medicine</i><br><i>Director, Hepatobiliary and Pancreatic Surgery</i><br><i>Professor of Surgery</i><br><i>Baltimore, Maryland</i>          |                                                                               |

## REGISTRATION INFORMATION

On-site registration for the Multidisciplinary Therapy of Pancreas Cancer Conference opens at 3:00 p.m. on Friday, May 3, 2019. The opening session will begin at 3:30 p.m. on Friday, May 3, 2019 and the conference will adjourn at 5:30 p.m., Saturday, May 4, 2019.

Advanced registration is encouraged as space and materials are limited. Please see registration form for applicable fees.

The deadline for advanced registration is **Friday, April 12, 2019**.

There are three ways to register:

1. On-line at [www.mdanderson.org/conferences](http://www.mdanderson.org/conferences)
2. Fax to: 713-794-1724
3. Mail to: Department of CME/Conference Management  
Unit 1781  
The University of Texas MD Anderson Cancer Center  
P.O. Box 301407  
Houston, TX 77230-1407

We accept the following forms of payment:

1. Check (payable through U.S. banks only)
2. Money Order
3. Credit Cards (MasterCard, VISA, and American Express)
4. Cash (on-site registration only)

When registering online a confirmation letter (receipt) will be automatically emailed to the email address you list on the registration form. The confirmation letter will serve as your receipt. If you register by fax or mail, a confirmation letter will be emailed to you within ten working days of receipt of your fee.

The full conference registration fee includes the tuition, final program, continental breakfast, breaks, lunch and welcome reception.

## REFUND/CANCELLATION POLICY

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before **April 12, 2019**. No refunds will be

granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.

In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. The Department of CME/Conference Management will refund the full registration fee. The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, contact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

## SPECIAL ASSISTANCE

Contact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

## ACCOMMODATIONS

- A block of rooms has been reserved for conference attendees at the **Hilton Houston Plaza/Medical Center Hotel**, 6633 Travis Street, Houston, Texas 77030.

- Early hotel reservation is suggested.
- The hotel phone number is 713-313-4000.
- When you make reservations be sure to mention **"MD Anderson Multidisciplinary Therapy of Pancreas Cancer Conference"** or Group Code: "PCC" to be assured of receiving the special meeting rate of \$129.00 single or double occupancy. Please add 17% Texas state and local taxes.
- Room Reservation Website Link: [Book your group rate for MD Anderson Multidisciplinary Therapy of Pancreas Cancer Conference](http://Book.your.group.rate.for.MD.Anderson.Multidisciplinary.Therapy.of.Pancreas.Cancer.Conference)
- Reservations and deposits received after **Thursday, April 11, 2019** will be confirmed if space is available and at current hotel published guest room rates.

## GROUND TRANSPORTATION

Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU). The following forms of ground transportation are available to and from the airports to the Medical Center.

- Uber and Lyft
- Taxicabs: Yellow Cab 713-236-1111; and Fiesta Cab 713-225-2666.
- Super Shuttle: For more information, call toll free at 800-258-3826, or on-line at [www.supershuttle.com](http://www.supershuttle.com)

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson/APAO may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

CONFERENCE REGISTRATION- D121582  
Multidisciplinary Therapy of Pancreas Cancer  
May 3-4, 2019

|                                                                                       |            |                                                                                                                  |      |                                                                    |
|---------------------------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------|------|--------------------------------------------------------------------|
| Last Name                                                                             |            | First                                                                                                            | MI   | Highest Degree                                                     |
| Department (include unit no.)                                                         |            | Specialty                                                                                                        |      |                                                                    |
| Institution                                                                           |            |                                                                                                                  |      |                                                                    |
| MD Anderson Employee ID No. (required for all MDACC employees):                       |            |                                                                                                                  |      | Physician <input type="checkbox"/> Yes <input type="checkbox"/> No |
| Street                                                                                |            |                                                                                                                  |      |                                                                    |
| City                                                                                  |            | State/Foreign Country/Zip or Mail Code                                                                           |      |                                                                    |
| Daytime Phone (with area code)                                                        |            | Fax (with area code)                                                                                             |      |                                                                    |
| E-mail Address (please print)                                                         |            |                                                                                                                  |      |                                                                    |
| Emergency Contact                                                                     |            | Phone (with area code)                                                                                           |      |                                                                    |
| Credit Card Holder Name (First/Last)                                                  |            | Charge the following:<br><input type="checkbox"/> VISA <input type="checkbox"/> MC <input type="checkbox"/> AMEX |      |                                                                    |
| Credit Card Number                                                                    |            | Expiration Date                                                                                                  |      |                                                                    |
| Security Code/CVV/CSV                                                                 |            | Credit Card Holder Billing Address & ZIP Code                                                                    |      |                                                                    |
| MD Anderson Interdepartmental Transfer (IDT) No.: *Fund Group 90 will not be accepted |            |                                                                                                                  |      |                                                                    |
| Business Unit                                                                         | Department | Fund Group *                                                                                                     | Fund | Fund Type                                                          |
| Authorized Signature REQUIRED for CREDIT CARD or IDT                                  |            | IDT Approver Name (First/Last) please print                                                                      |      |                                                                    |

THIS IS NOT A SELF-MAILER - Address to:  
Multidisciplinary Therapy of Pancreas Cancer:  
RECENT ADVANCES AND EMERGING PARADIGMS  
May 3-4, 2019

Department of CME/Conference Management – Unit 1781  
The University of Texas MD Anderson Cancer Center  
PO Box 301407, Houston, TX 77230-1407  
or fax to 713-794-1724

Make check or money order payable to:

The University of Texas MD Anderson Cancer Center

Registration Fees

Physicians/Scientists

☐ Postmarked on or before April 12, 2019 .....\$200.00  
☐ Postmarked after April 12, 2019 .....\$250.00

Nurses/APPs

☐ Postmarked on or before April 12, 2019 .....\$75.00  
☐ Postmarked after April 12, 2019 .....\$125.00

Students/Fellows/Residents

☐ Postmarked on or before April 12, 2019 .....\$50.00  
☐ Postmarked after April 12, 2019 .....\$100.00

MDACC Faculty

☐ Postmarked on or before April 12, 2019 .....\$150.00  
☐ Postmarked after April 12, 2019 .....\$200.00

MDACC Nurses/APPs

☐ Postmarked on or before April 12, 2019 .....\$50.00  
☐ Postmarked after April 12, 2019 .....\$100.00

MDACC Students/Fellows/Residents

☐ Postmarked on or before April 12, 2019 .....\$25.00  
☐ Postmarked after April 12, 2019 .....\$75.00

Attending Friday Reception?.....☐ Yes ☐ No

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

Department of CME/Conference Management- Unit 1781  
The University of Texas MD Anderson Cancer Center  
176700/30/121582/41  
PO Box 301407  
Houston, TX 77230-1407

---

Non-Profit Org.  
U.S. Postage  
PAID  
Houston, TX  
Permit No. 7052